Metabolomic Identification of Exosome-Derived Biomarkers for Schizophrenia: A Large Multicenter Study.

ABSTRACT: Exosomes have been suggested as promising targets for the diagnosis and treatment of neurological diseases, including schizophrenia (SCZ), but the potential role of exosome-derived metabolites in these diseases was rarely studied. Using ultra-performance liquid chromatography-tandem mass spectrometry, we performed the first metabolomic study of serum-derived exosomes from patients with SCZ. Our sample comprised 385 patients and 332 healthy controls recruited from 3 clinical centers and 4 independent cohorts. We identified 25 perturbed metabolites in patients that can be used to classify samples from patients and control participants with 95.7% accuracy (95% CI: 92.6%-98.9%) in the training samples (78 patients and 66 controls). These metabolites also showed good to excellent performance in

SUBMITTER: Du Y 

PROVIDER: S-EPMC8084447 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature